FENNEC PHARMACEUTICALS INC. 8-K

What Happened
Fennec Pharmaceuticals, Inc. (FENC) filed an 8‑K on May 18, 2026 to report that its board approved stock option grants totaling 50,000 common shares to three new employees. The awards were made as inducement awards under the Company’s 2026 Equity Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). A related press release was furnished as Exhibit 99.1.

Key Details

• Total options granted: 50,000 options to three new employees (grant date May 18, 2026).
• Exercise price: $9.75 per share.
• Term and vesting: 10‑year term; vesting over three years — one‑third vests on the first anniversary, remainder vests monthly over the next 24 months, subject to continued employment.
• Regulatory note: Awards were made as Nasdaq inducement awards; press release furnished as Exhibit 99.1 (Item 8.01 states that the press release is furnished, not “filed,” for certain legal purposes).

Why It Matters
These option grants are a form of employee compensation intended to attract and retain new hires. If all options are exercised, up to 50,000 additional common shares could be issued, which would increase the company’s outstanding share count (dilution). Investors should note the exercise price, vesting schedule and that these are inducement awards under Nasdaq rules; the filing does not include financial results or other operational updates.